POCT Product Overseas Registration: How to Prepare Registration Dossiers?

The core of overseas registration for POCT (Point-of-Care Testing) products is to identify the specific regulatory requirements of the target country and systematically prepare technical documentation, quality management system evidence, clinical evaluation files, and labeling/instructions for use. Manufacturers must first determine whether the product is classified as a medical device or in vitro diagnostic (IVD) product, and then identify the appropriate registration pathway based on risk class (e.g., EU CE under IVDR, US FDA 510(k), Australia TGA, Southeast Asian country registrations). Typical dossiers include product description, intended use, risk management report, performance evaluation (precision, accuracy, linearity, reference intervals, etc.), stability studies, clinical evaluation or clinical trial reports, software validation (if applicable), production process and quality control documents, labeling and IFU, packaging validation, ISO 13485 or MDSAP certificates, and local authorized representative/agent information. Key areas of focus include: (1) differences in clinical evidence requirements among countries (e.g., EU requires performance evaluation, US requires clinical performance studies); (2) language translation and localization (IFU and labels must be in the target country language); (3) post-market surveillance (PMS/PMCF) plans. Common risks include incomplete technical documentation (e.g., lack of linkage between risk management and performance evaluation), insufficient clinical evidence, QMS non-compliance with local regulations, and failure to appoint a local agent. Early planning for document reuse and localization conversion can significantly reduce multi-country registration costs.

Applicable Scenarios and Core Questions

POCT products requiring overseas registration include self-monitoring blood glucose meters, rapid diagnostic reagents, blood gas analyzers, cardiac marker tests, and other point-of-care devices. Manufacturers often encounter core questions such as: Which medical device or IVD category does the product fall under in each target country? What registration pathway applies? Can technical files be reused? What level of clinical evidence is required? How should labeling and IFU be localized? These questions directly affect registration timelines and costs.

This article is intended for manufacturers planning to export POCT products to the EU, United States, Southeast Asia, the Middle East, Latin America, and other markets. It focuses on the key aspects of preparing registration dossiers and common pitfalls.

Registration Decision Logic

Step 1: Confirm whether the product is a medical device or in vitro diagnostic. Definitions differ by country; for example, the US FDA may classify certain POCT products as medical devices, while the EU IVDR applies directly.

Step 2: Determine classification based on risk (e.g., EU IVDR classes A–D; US FDA classes I–III).

Step 3: Select the registration pathway. For EU CE, a notified body review is typically required for Class B and above. For US FDA 510(k), substantial equivalence to a legally marketed predicate device must be demonstrated. Australia TGA requires assessment of QMS and performance.

Step 4: Evaluate existing documentation. If the manufacturer holds an NMPA registration certificate, CE technical files, FDA submission files, ISO 13485 certificates, or MDSAP certificates, portions of this content may be reused, but differences must be addressed.

Step 5: Confirm local agent/authorized representative requirements (mandatory in many countries) and plan post-market surveillance documentation.

For example, in the EU, POCT products typically fall under IVDR. Manufacturers must provide a performance evaluation report, risk management report, clinical evidence (performance evaluation or clinical trial), and a QMS ISO 13485. In the US, a 510(k) submission is required, including product description, performance data, labeling, and evidence of substantial equivalence to a predicate. Many Southeast Asian countries accept CE or FDA documentation, but additional local registration and appointment of a local agent are required.

Documentation and Evidence

Basic Technical Documents

Product description (principle, composition, intended use), classification rationale, General Safety and Performance Requirements (GSPR) checklist, and risk management file per ISO 14971 (risk identification, evaluation, control measures). Performance evaluation documents: precision, accuracy, linearity, interference, reference intervals, and stability (real-time, accelerated, transport). For quantitative assays, metrological traceability and calibration control material assignment must be provided.

Software Documentation (if applicable)

Software version, validation report, and cybersecurity information.

Clinical Evidence

Under the EU IVDR, clinical performance studies are required; if a comparable device is already on the market, literature data may be cited. The US FDA typically requires clinical performance data (e.g., comparison with a reference method).

Quality Management System

ISO 13485 certificate, MDSAP certificate (helpful for multi-country registrations), and QMS documentation (design controls, production controls, corrective and preventive actions).

Labeling and IFU

Must be provided in the original and target country languages and comply with local regulations (e.g., EU requires multiple languages; US specifies English font sizes).

Other Documents

Packaging validation report, batch records, supplier audit records, local authorized representative/agent information and agency agreement, post-market surveillance (PMS) plan, and periodic safety update report (PSUR) template.

Common Errors

• Misclassification: Different countries classify POCT products differently, leading to incorrect registration pathways. For example, the same product may be Class B in the EU but Class II in the US, requiring different documentation.
• Incomplete Technical Files: Missing linkage between risk management and performance evaluation, or stability data not meeting local climatic zone requirements.
• Insufficient Clinical Evidence: The EU IVDR raises requirements; some manufacturers attempt to use old IVDD data, resulting in deficiency letters.
• Translation Errors: Inaccurate labeling and IFU translations can cause misleading information or fail to meet local language requirements.
• Failure to Appoint a Local Authorized Representative: Some manufacturers assume they can self-register, ignoring mandatory requirements.
• QMS Non-conformity: Not updating to ISO 13485:2016 or MDSAP requirements.

Manufacturer Preparation Checklist

• Define target country registration classification and pathway.
• Prepare basic technical documents (product description, intended use).
• Develop a risk management report per ISO 14971.
• Complete performance evaluations (precision, accuracy, linearity, interference, reference intervals, stability).
• Gather or generate clinical evidence (clinical performance study or literature).
• Obtain ISO 13485 and/or MDSAP certificates.
• Design labeling and IFU to meet target country regulations (translate and validate).
• Appoint a local authorized representative/agent and sign an agreement.
• Write post-market surveillance (PMS) plans and periodic report templates.
• Compile packaging validation, production process files, and supplier qualifications.

AIMEILI Regulatory Interpretation and Business Impact

In overseas registration of POCT products, manufacturers most frequently misjudge clinical evidence requirements. Many assume that an NMPA registration certificate is sufficient to cover overseas markets; however, especially after the EU IVDR transition, clinical performance evidence requirements have increased significantly. At the early stage of a project, manufacturers should prioritize a gap analysis between existing documentation and international standards, focusing on the linkage between risk management and performance evaluation, as well as the acceptability of clinical evidence. It is recommended to conduct a gap assessment before deciding whether additional experiments or literature collection are needed.

Regarding document reuse: ISO 13485 certificates, MDSAP certificates, and basic performance evaluation data (precision, accuracy) can be widely reused. However, risk management files, clinical evidence, and labeling/IFU must be localized. For example, in the EU, documentation must be formatted per IVDR; in the US, the emphasis is on equivalence to a predicate device. Local agents and authorized representatives are not only legal requirements but also critical control points for changes and renewals. Neglecting the qualification and responsibilities of an agent could lead to certificate cancellation.

For multi-country registration, using a Summary Technical Documentation (STED) format as a foundation, supplemented by country-specific localization, can significantly reduce repetitive work and deficiency risks, shortening overall timelines. AIMEILI recommends that manufacturers complete registration in one priority country first, gain experience, and then replicate the process in other markets.

Frequently Asked Questions

Q: My POCT product is already registered in China. Can I use those documents directly for overseas registration?

Not directly, but partial reuse is possible. Technical documents from domestic registration (e.g., performance evaluation, stability data) can serve as important references. However, clinical evidence must meet local requirements; risk management and QMS must align with international versions of ISO 14971 and ISO 13485; labeling and IFU must be translated and comply with local regulations.

Q: Which countries accept CE or FDA registration documentation?

Many Southeast Asian countries (e.g., Thailand, Indonesia, Philippines), Middle East (e.g., Saudi Arabia, UAE), and Latin American countries (e.g., Brazil, Mexico) typically accept CE or FDA assessments. However, they require a local agent, translated registration documents, and may require on-site audits or local clinical data. Some countries also require that the product be already marketed in the country of origin.

Q: Should POCT products undergo clinical trials or performance evaluations?

It depends on target country regulations and product risk. Under the EU IVDR, most POCT products can satisfy clinical evidence requirements through performance evaluation (literature, published standards, comparison with a reference method), provided equivalence to an existing product is demonstrated or recognized reference standards are used. The US FDA generally requires clinical performance studies (e.g., comparison with a gold standard) unless the product is exempt. It is advisable to consult MDR/IVDR guidelines and relevant guidance documents.